Kalamazoo, Michigan - March 1, 2013 - Stryker Corporation (NYSE:SYK) announced
today the successful completion of its previously announced voluntary general
offer to acquire Trauson Holdings Company Limited (Trauson). Trauson is the
leading trauma manufacturer in China and a major competitor in the spine
segment.

"With the acquisition of Trauson, we are well positioned to broaden our presence
in China and to expand into the fast growing value segment of the emerging
markets. We look forward to building on the company's long history of success,"
said Kevin A. Lobo, President and Chief Executive Officer.
As indicated in the January 17, 2013 press release, the transaction is expected
to be neutral to Stryker's 2013 earnings per share excluding acquisition and
integration-related charges.

Stryker is one of the world's leading medical technology companies and is
dedicated to helping healthcare professionals perform their jobs more
efficiently while enhancing patient care. The Company offers a diverse array of
innovative medical technologies, including reconstructive, medical and surgical,
and neurotechnology and spine products to help people lead more active and more
satisfying lives. For more information about Stryker, please visit
www.stryker.com.

Contacts

For investor inquiries please contact:
Katherine A. Owen, Stryker Corporation, 269-385-2600 or
katherine.owen@stryker.com

This press release contains information that includes or is based on forward-
looking statements within the meaning of the federal securities law that are
subject to various risks and uncertainties that could cause our actual results
to differ materially from those expressed or implied in such statements. Such
factors include, but are not limited to: weakening of economic conditions that
could adversely affect the level of demand for our products; pricing pressures
generally, including cost-containment measures that could adversely affect the
price of or demand for our products; changes in foreign exchange markets;
legislative and regulatory actions; unanticipated issues arising in connection
with clinical studies and otherwise that affect U.S. Food and Drug
Administration approval of new products; changes in reimbursement levels from
third-party payors; a significant increase in product liability claims; the
ultimate total cost with respect to the Rejuvenate and ABG II matter; the impact
of investigative and legal proceedings and compliance risks; resolution of tax
audits; the impact of the federal legislation to reform the United States
healthcare system and the 2.3 percent medical device excise tax; changes in
financial markets; changes in the competitive environment; our ability to
integrate acquisitions, including the acquisition of Trauson Holdings Company
Limited; and our ability to realize anticipated cost savings as a result of
workforce reductions and other restructuring activities. Additional information
concerning these and other factors are contained in our filings with the U.S.
Securities and Exchange Commission, including our Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q.





This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
    other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
     originality of the information contained therein.

Source: Stryker Corporation via Thomson Reuters ONE
[HUG#1682349]